The Food and Drug Administration (FDA) has approved the first clinical test that uses DNA to assess potential risk of opioid use disorder in certain patients, according to an FDA announcement. The new AvertD test is intended as a screening tool clinicians can use before prescribing oral opioid drugs in adult patients who are being considered for short-term treatment of acute pain and who have not previously used oral opioid pain medications. To administer at …
Read More